Table of Contents
What is the function of MET?
MET regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells. It also contributes to PD-L1-mediated suppression of immune cell function. C-Met is the downstream target of microRNA-449b-5p, and its level was inhibited in OS cells overexpressing microRNA-449b-5p.
Is MET a receptor?
MET is a receptor tyrosine kinase (RTK) that is produced as a single-chain precursor. The precursor is proteolytically cleaved at a furin site to yield a highly glycosylated extracellular α-subunit and a transmembrane β-subunit, which are linked together by a disulfide bridge.
What is MET in biology?
A mesenchymal–epithelial transition (MET) is a reversible biological process that involves the transition from motile, multipolar or spindle-shaped mesenchymal cells to planar arrays of polarized cells called epithelia.
What is MET oncology?
MET is a tyrosine kinase receptor involved in cell proliferation, survival, and migration. MET pathway is activated in cancer by gene amplification and overexpression, ligand overexpression and autocrine/paracrine activation, and activating MET mutations.
What is MET mutation?
A gene that makes a protein that is involved in sending signals within cells and in cell growth and survival. Mutated (changed) forms of the MET gene may cause abnormal cells to grow and spread in the body.
What is the difference between MET and c-Met?
c-met or c-Met (all symbols written in italic!) is referred to the gene; in this case to a proto-oncogene because of the presence of “c-” in the symbol. MET is the abbreviation of Mesenchymal to Epithelial Transition (biological process).
What does the Met gene code for?
UniProtKB/Swiss-Prot Summary for MET Gene Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival.
Is MET an oncogene?
Patients with HPRC have an increased risk of a type of kidney cancer called papillary renal carcinoma. MET gene mutations have also been found in liver cancer and head and neck cancer. The MET gene is a type of proto-oncogene and a type of receptor tyrosine kinase gene.
What is a MET amplification?
MET Amplification is a predictive biomarker for use of capmatinib, crizotinib, afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib in patients. Of the therapies with MET Amplification as a predictive biomarker, 7 have NCCN guidelines in at least one clinical setting.
WHAT IS MET amplification NSCLC?
MET amplification is a potential resistance pattern of EGFR-TKIs in NSCLC, accounting for 50–60% of the first- and second-generation EGFR-TKIs acquired resistance,31,32,84 accounting for 15–19% of the third-generation EGFR-TKIs acquired resistance.
Where is C-met expressed?
The protein product of this gene is the c-MET tyrosine kinase. This cell surface receptor is expressed in epithelial cells of many organs, including the liver, pancreas, prostate, kidney, muscle and bone marrow, during both embryogenesis and adulthood [Comoglio et al.
How does the Met pathway affect the development of cancer?
MET pathway plays an important role in the development of cancer through: scatter (cells dissociation due to metalloprotease production), which often leads to metastasis.
Are there any drugs that are considered met?
Various common drugs were considered that would potentially benefit these problems, improve spontaneous stone passage, and alleviate renal colic discomfort. Although NSAIDs have ureteral-relaxing effects and, as such, can be considered a form of MET, they are not generally considered MET.
How does met activate multiple signal transduction pathways?
MET engagement activates multiple signal transduction pathways: The RAS pathway mediates HGF-induced scattering and proliferation signals, which lead to branching morphogenesis. Of note, HGF, differently from most mitogens, induces sustained RAS activation, and thus prolonged MAPK activity.
How is met activated in the invasive growth program?
MET activation by its ligand HGF induces MET kinase catalytic activity, which triggers transphosphorylation of the tyrosines Tyr 1234 and Tyr 1235. These two tyrosines engage various signal transducers, thus initiating a whole spectrum of biological activities driven by MET, collectively known as the invasive growth program.